Budget impact analysis second class reimbursement submission of injectable long-acting schizophrenia maintenance treatment drug in Belgium.

The aim of the project for Hict was to provide support for the BIA and the price strategy.

In an intake phase, Hict determined the general strategy and the key elements of the BIA: identification of

• correct comparators
• different product values to include in the BIA
• requested clinical, epidemiological and cost data for the BIA
• current available sources for clinical data, epidemiological data & cost data
• possible price strategies
  
  

In the subsequent phase, Hict was responsible for

• data collection & processing of this data
• development of the BIA model
• population of the model with the collected data
• development of a report detailing the BIA and its results

Approach

In the intake phase, based on desk research and literature search, the most appropriate approach and strategy for the BIA in the reimbursement dossier of Abilify Maintena® was defined in cooperation with Lundbeck.

Second, the necessary data collection & processing was done based on desk research. An analysis of the reimbursement criteria of the comparators and existing market researches was performed, together with research on Belgian prevalence data, resource use and unit costs.

Subsequently, the BIA model was developed and populated with the collected Belgian data. A validation of the generated results was performed internally and with Lundbeck.

Finally, an extensive report was written, discussing in detail all aspects of the BIA model, together with the used data, values and sources. The report and the detailed BIA model was delivered and presented to Lundbeck.